NEW YORK (AP) — Danish drugmaker Novo Nordisk A/S said Tuesday that the Food and Drug Administration granted an additional marketing approval for its diabetes drug Levemir.
Novo Nordisk says Levemir is now approved for use in children with type 1 diabetes from age 2 to 5. Levemir is an injectable form of insulin and it was already approved for type 1 diabetes patients age 5 and older, and for adults with type 2 diabetes. The company said Levemir is the only basal insulin approved for children as young as 2 years.
U.S. shares of Novo Nordisk fell $1.06 to $144.01 in morning trading Tuesday. Its shares peaked for the past year at $152.31 in mid-April but are up from their low of $94.58 in early October.